OBE022
Modify Date: 2024-01-06 20:20:05
OBE022 structure
|
Common Name | OBE022 | ||
|---|---|---|---|---|
| CAS Number | 2005486-32-6 | Molecular Weight | 636.194 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H35ClFN3O5S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OBE022OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes; inhibits spontaneous, oxytocin- and PGF2α-induced human myometrial contractions alone and is more effective in combination with atosiban or nifedipine; reduces spontaneous contractions in near-term pregnant rat, OBE022 delayed RU486-induced parturition and exerted synergistic effects in combination with nifedipine; exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects. Other Indication Phase 2 Clinical |
| Name | OBE022 |
|---|
| Description | OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM, shows no activity for other human PG receptors subtypes; inhibits spontaneous, oxytocin- and PGF2α-induced human myometrial contractions alone and is more effective in combination with atosiban or nifedipine; reduces spontaneous contractions in near-term pregnant rat, OBE022 delayed RU486-induced parturition and exerted synergistic effects in combination with nifedipine; exhibits potent tocolytic effects on human tissues ex vivo and animal models in vivo without causing the adverse fetal side effects. Other Indication Phase 2 Clinical |
|---|---|
| References | References 1. Pohl O, et al. J Pharmacol Exp Ther. 2018 May 18. pii: jpet.118.247668. 2. Pohl O, et al. Br J Clin Pharmacol. 2018 Apr 30. doi: 10.1111/bcp.13622. View Related Products by Target Prostaglandin Receptor Other Indication |
| Molecular Formula | C30H35ClFN3O5S2 |
|---|---|
| Molecular Weight | 636.194 |